SAN DIEGO, Feb. 23, 2026 /PRNewswire/ — Avidity Biosciences, Inc. (“Avidity”) (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (“AOCs™”) to profoundly improve people’s lives, today announced that…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
